Abstract
A first-in-class guanylate cyclase-C agonist, linaclotide (Linzess—Forest, Ironwood), has been approved to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults. Linaclotide, which is minimally absorbed, acts locally in the intestine to increase both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
